Top 11 Small Cap Stocks to Buy with Biggest Upside Potential

Page 9 of 10

2. Cartesian Therapeutics, Inc. (NASDAQ:RNAC)

Market Cap: $318.25 million

Analyst Upside: 233.33%

Number of Hedge Fund Holders: 7

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a clinical-stage biotechnology company that provides mRNA cell therapies to treat autoimmune diseases. The company operates in the development and research of cell therapy product candidates. It ranks second on our list of the best small-cap stocks to buy with the biggest upside potential.

On April 10, Leerink Partners analyst Thomas Smith reiterated their bullish stance on the company, giving it a Buy rating. The analyst said that promising long-term data from Cartesian Therapeutics, Inc.’s (NASDAQ:RNAC) Phase 2b trial of Descartes-08 for treating myasthenia gravis supports this rating. The results show durable and significant decreases in key efficacy endpoints, indicating a strong therapeutic effect. Most importantly, the data shows a favorable safety profile, reporting no new safety concerns like CRS or ICANS. According to the analyst, this supports the potential for outpatient administration without the need for lymphodepletion.

Descartes-08 also holds a competitive market advantage, as trial results show a competitive depth of response and promising durability. Various other factors also point towards a positive outlook for Cartesian Therapeutics, Inc. (NASDAQ:RNAC), including the anticipation of further clinical data, including re-treatment and crossover experiences, and the upcoming Phase 3 AURORA trial.

Page 9 of 10